Eloxx Pharmaceuticals (NASDAQ:ELOX) Rating Increased to Strong-Buy at Lucid Cap Mkts

Eloxx Pharmaceuticals (NASDAQ:ELOX) was upgraded by analysts at Lucid Cap Mkts to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

ELOX has been the topic of several other reports. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a research report on Saturday, August 1st. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective for the company. Guggenheim began coverage on Eloxx Pharmaceuticals in a research note on Monday, July 20th. They set a “buy” rating and a $43.00 price objective for the company. Finally, Weiss Ratings started coverage on shares of Eloxx Pharmaceuticals in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Eloxx Pharmaceuticals Stock Up 16.3%

Shares of NASDAQ:ELOX opened at $20.98 on Thursday. The company has a market capitalization of $84.76 million, a PE ratio of -13.62 and a beta of -1,864.08. The company’s 50-day moving average is $14.32. Eloxx Pharmaceuticals has a 12-month low of $8.20 and a 12-month high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last released its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.